deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03012620

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types (AcSé)

Sponsor: Ligue contre le cancer, France

Conditions Carcinoma, Neuroendocrine Central Nervous System Neoplasm NK/T-cell Lymphoma Neoplasms, Germ Cell and Embryonal Ovarian Neoplasm Sarcoma Thyroid Neoplasm
Interventions Pembrolizumab
Updated 13 times since 2017 Last updated: Feb 26, 2024 Started: Jul 5, 2017 Primary completion: Dec 26, 2022 Completion: Dec 14, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03012620, this PHASE2 trial focuses on Carcinoma, Neuroendocrine and Central Nervous System Neoplasm and remains completed. Sponsored by Ligue contre le cancer, France, it has been updated 13 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Dec 2019 · 18 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2022 · 13 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Mar 2023 · 9 months · monthly snapshot~Mar 2023 – ~Mar 2024 · 12 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Mar 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 8 earlier versions

  1. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  4. Dec 2019 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Jun 2018 — Dec 2019 [monthly]

    Recruiting PHASE2

  6. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jul 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE2

  8. Feb 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ligue contre le cancer, France
  • Merck Sharp & Dohme LLC
  • National Cancer Institute, France
  • UNICANCER
Data source: UNICANCER

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations